RxDoctor Payments Data

Erik Johnson, MD

Family Medicine · Houston, TXNPI 1164409355

Payments from drug & device makers

$738in general payments, 2019–2025

Across 33 payments — averaging $22.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$135
  • Bayer$124
  • Abbott$74
  • Baxter Healthcare$63
  • Novo Nordisk$42
  • Lilly USA, LLC$39
  • plus $262 from 10 others

What the payments were for

  • Food & beverage$72498%
  • Entertainment$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$738 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$7,033
Medicare patients
33
Services billed
77

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$67,994
JardianceEmpagliflozin71$57,760
EliquisApixaban41$46,264
TrulicityDulaglutide35$37,832
XareltoRivaroxaban15$21,379
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$20,287
MounjaroTirzepatide20$19,674
JanuviaSitagliptin Phosphate20$18,607
FarxigaDapagliflozin Propanediol11$11,967
EntrestoSacubitril/Valsartan11$10,401
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$6,913
Combivent RespimatIpratropium/Albuterol Sulfate14$6,729
Gabapentin250$5,272
Esomeprazole Magnesium36$3,479
Advair DiskusFluticasone Propion/Salmeterol16$3,466

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$42$67,99448 claims
Boehringer IngelheimJardiance, Combivent Respimat$35$64,48985 claims
Lilly USA, LLCTrulicity, Mounjaro$39$57,50655 claims
AstraZenecaFarxiga$32$11,96711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →